Education
About Us
Working with TipRanks
Follow Us
Living Cell Technologies Ltd. (AU:1AI)
ASX:1AI
1AI Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume31.97M
Average Volume (3M)2.98M
Market Cap
AU$25.75M
Enterprise ValueAU$24.56M
Total Cash (Recent Filing)AU$1.88M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding1,716,791,100
10 Day Avg. Volume1,972,597
30 Day Avg. Volume2,982,772
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-10.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtAbsence of debt materially reduces fixed obligations and bankruptcy risk for a development-stage biotech. With no interest burden, management can allocate scarce cash to R&D or trials, preserving runway and strategic optionality to pursue partnerships or milestone-based financings over the next 2–6 months.
Narrowing Net LossesA meaningful narrowing of net losses signals improving cost structure or milestone-driven progress. This trend, if sustained, reduces future funding needs and indicates management execution on expense control or development efficiency, improving survival odds during extended clinical timelines.
Focused Regenerative-Medicine PipelineA concentrated platform in cell-based regenerative therapies targets chronic, high-unmet-need indications with structural demand. Scientific specialization creates high technical barriers and differentiation, supporting long-term partnership and licensing opportunities that can fund development and eventual commercialization.
Bears Say
Effectively No RevenueLack of recurring or product revenue means the business remains pre-commercial and dependent on external capital. Over a multi-month horizon, absence of commercial cash inflows makes forecasting viability harder and increases execution risk until regulatory approval or licensing deals generate sustainable revenue.
Persistent Negative Cash FlowConsistent negative operating and free cash flow indicate ongoing cash burn and limited internal funding capacity. This structural shortfall necessitates regular equity or partnership financing, raising dilution and execution risk and constraining the company's ability to scale trials or commercialization in the medium term.
Eroding Equity And Shrinking AssetsDeclining equity and reduced asset base weaken financial flexibility and collateral for partnerships or credit. Over a 2–6 month horizon, this erosion heightens the likelihood of urgent financing, limits negotiating leverage with partners, and can force unfavorable funding terms that impair long-term strategy.
Living Cell Technologies News
1AI FAQ
What was Living Cell Technologies Ltd.’s price range in the past 12 months?
Living Cell Technologies Ltd. lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Living Cell Technologies Ltd.’s market cap?
Living Cell Technologies Ltd.’s market cap is AU$25.75M.
When is Living Cell Technologies Ltd.’s upcoming earnings report date?
Living Cell Technologies Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 171 days.
How were Living Cell Technologies Ltd.’s earnings last quarter?
Living Cell Technologies Ltd. released its earnings results on Mar 04, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Living Cell Technologies Ltd. overvalued?
According to Wall Street analysts Living Cell Technologies Ltd.’s price is currently Overvalued.
Does Living Cell Technologies Ltd. pay dividends?
Living Cell Technologies Ltd. does not currently pay dividends.
What is Living Cell Technologies Ltd.’s EPS estimate?
Living Cell Technologies Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Living Cell Technologies Ltd. have?
Living Cell Technologies Ltd. has 1,716,791,100 shares outstanding.
What happened to Living Cell Technologies Ltd.’s price movement after its last earnings report?
Living Cell Technologies Ltd. reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went up 6.667%.
Which hedge fund is a major shareholder of Living Cell Technologies Ltd.?
Currently, no hedge funds are holding shares in AU:1AI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Living Cell Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:1AI Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-49.25%
Trailing 12-Months
Asset Growth
-15.04%
Trailing 12-Months
Company Description
Living Cell Technologies Ltd.
Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Sydney, Australia.
Technical Analysis
Invex Therapeutics Ltd.
―
Regeneus Ltd.
―
Chimeric Therapeutics Ltd.
―
Neuroscientific Biopharmaceuticals Ltd.
―
Memphasys Ltd
―